KR880005131A - 1-히드록시알킬크산틴류, 그의 제조방법 및 그를 함유한 의약품 - Google Patents

1-히드록시알킬크산틴류, 그의 제조방법 및 그를 함유한 의약품 Download PDF

Info

Publication number
KR880005131A
KR880005131A KR870011905A KR870011905A KR880005131A KR 880005131 A KR880005131 A KR 880005131A KR 870011905 A KR870011905 A KR 870011905A KR 870011905 A KR870011905 A KR 870011905A KR 880005131 A KR880005131 A KR 880005131A
Authority
KR
South Korea
Prior art keywords
compound
hydroxybutyl
methylxanthine
alkyl group
hydroxypropyl
Prior art date
Application number
KR870011905A
Other languages
English (en)
Other versions
KR930010559B1 (ko
Inventor
래네 후메옥스
조르쥐 필리포시안
Original Assignee
앙드르제이 레드지용
소시에떼 데 프로듀이 네슬레 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앙드르제이 레드지용, 소시에떼 데 프로듀이 네슬레 소시에떼 아노님 filed Critical 앙드르제이 레드지용
Publication of KR880005131A publication Critical patent/KR880005131A/ko
Application granted granted Critical
Publication of KR930010559B1 publication Critical patent/KR930010559B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용 없음

Description

1-히드록시알킬크산틴류, 그의 제조방법 및 그를 함유한 의약품
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 하기 일반식(I)의 화합물 또는 생리적으로 수용 가능한 그의 염.
    (상기식중, R1은 C2∼C5W-히드록시-n-알킬기 또는 C3∼C5(W-1)-히드록시-n-알킬기이고, R3는 C1∼C4알킬기이며, R8은 H, 메틸 또는 에틸이고, R1및 R3에서 탄소 원자의 합은 4∼9이다)
  2. 제1항에 있어서, 1-(2-히드록시에틸)-3-프로필크산틴, 1-(2-히드록시에틸)-3-이소부틸크산틴, 1-(2-히드록시에틸)-3-이소부틸-8-메틸크산틴, 1-(2-히드록시프로필)-3-프로필크산틴, 1-(2-히드록시프로필)-3-프로필-8-메틸크산틴, 1-(2-히드록시프로필)-3-부틸크산틴, 1-(3-히드록시프로필)-3-프로필크산틴, 1-(3-히드록시프로필)-3-프로필-8-메틸크산틴, 1-(3-히드록시프로필)-3-프로필-8-에틸크산틴, 1-(3-히드록시프로필)-3-부틸크산틴, 1-(3-히드록시프로필)-3-이소부틸크산틴, 1-(3-히드록시프로필)-3-이소부틸-8-메틸크산틴, 1-(3-히드록시부틸)-3-메틸크산틴, 1-(3-히드록시부틸)-3-에틸크산틴, 1-(3-히드록시부틸)-3-에틸-8-메틸크산틴, 1-(3-히드록시부틸)-3-프로필크산틴, 1-(3-히드록시부틸)-3-이소부틸크산틴, 1-(4-히드록시부틸)-3-에틸크산틴, 1-(4-히드록시부틸)-3-프로필크산틴, 1-(4-히드록시부틸)-3-프로필-8-메틸크산틴, 1-(4-히드록시부틸)-3-부틸크산틴, 1-(4-히드록시부틸)-3-이소부틸-8-메틸크산틴, 1-(4-히드록시펜틸)-3-메틸크산틴, 1-(4-히드록시부틸)-3-이소부틸-8-메틸크산틴, 1-(4-히드록시펜틸)-3-메사크산틴, 1-(4-히드록시펜틸)-3-프로필크산틴, 1-(5-히드록시펜틸)-3-메틸크산틴, 1-(5-히드록시펜틸)-3-프로필크산틴, 및 1-(5-히드록시펜틸)-3-프로필-8-메틸크산틴의 군에서 선택된 화합물.
  3. A) 하기 일반식(II)의 화합물을 일반식 R1-X의 알킬화제와 반응시키고, 수득된 화합물을 고리화하거나
    (상기 식중, R1, R3및 R8은 하기에 정의하는 바와 같고 (단 R1은 W-히드록시부틸이 아니다), X는 할로겐원자, 모노 설페이트 또는 디설페이트 또는 P-톨루엔술포네이트이다), B) 하기 일반식(II)의 화합물을 일반식 X-(CH2)y-COO-R4의 알킬화제와 반응시키고, 수득된 화합물을 수성 알칼리성 매질에서 고리화하여 하기 일반식(V)의 화합물을 수득한 후, 수득된 화합물(V)를 에스테르화 하고, 수득된 에스테르를 환원시켜 R1이 -(CH2)y-CH2-OH인 화합물(I)을 제조하거나
    (상기식중, R3및 R8은 하기에 정의하는 바와 같고, X는 상기에 정의한 바와 같으며, y는 1∼4의 수이고, R4는 알킬이다), C) 하기 일반식(II)의 화합물을 일반식 R5X의 알킬화제와 반응시키고, 수득된 화합물을 고리화 한 후, 말코프니코프형의 첨가 반응에 의해 R5의 이중 결합을 수화하여 R1이 C3∼C5(W-1)-히드록시-n-알킬기인 화합물(I)을 제조
    (상기식중, R3및 R8은 하기에 정의하는 바와 같고, X는 상기에 정의한 바와 같으며, R5는 C3∼C5알케닐기이다)함을 특징으로 하는 하기 일반식(I)의 화합물 또는 생리학적으로 수용가능한 그의 염의 제조방법.
    (상기식중, R1은 C2∼C5W-히드록시-n-알킬기 또는 C3-C5(W-1)-히드록시-n-알킬기이며, R3는 C1∼C4알킬기이고, R8은 H, 메틸 또는 에틸이며, R1및 R3에서 탄소원자의 합은 4∼9이다).
  4. 하기 일반식(I)의 화합물 또는 생리학적으로 수용 가능한 그의 염을 약학적으로 수용가능한 부형제와 함께 함유하는 약학 조성물.
    (상기식중, R1은 C2∼C5W-히드록시-n-알킬기 또는 C3-C5(W-1)-히드록시-n-알킬기이고, R3는 C1∼C4알킬기이며, R8은 H, 메틸 또는 에틸이며, R1및 R3에서 탄소원자의 합은 4(9이다).
  5. 제4항에 있어서, 제2 또는 3항에 기재된 종류의 화합물을 함유하는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870011905A 1986-10-27 1987-10-26 1-히드록시알킬크산틴류, 그의 제조방법 KR930010559B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH4253/86-8 1986-10-27
CH4253/86A CH670090A5 (ko) 1986-10-27 1986-10-27

Publications (2)

Publication Number Publication Date
KR880005131A true KR880005131A (ko) 1988-06-28
KR930010559B1 KR930010559B1 (ko) 1993-10-28

Family

ID=4272668

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870011905A KR930010559B1 (ko) 1986-10-27 1987-10-26 1-히드록시알킬크산틴류, 그의 제조방법

Country Status (13)

Country Link
EP (1) EP0269841B1 (ko)
JP (1) JP2527769B2 (ko)
KR (1) KR930010559B1 (ko)
AT (1) ATE82289T1 (ko)
AU (1) AU604767B2 (ko)
CA (1) CA1296001C (ko)
CH (1) CH670090A5 (ko)
DE (1) DE3782619T2 (ko)
DK (1) DK169336B1 (ko)
ES (1) ES2043631T3 (ko)
GR (1) GR3006223T3 (ko)
IL (1) IL84266A (ko)
ZA (1) ZA877851B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same

Also Published As

Publication number Publication date
ATE82289T1 (de) 1992-11-15
ES2043631T3 (es) 1994-01-01
IL84266A0 (en) 1988-03-31
DK169336B1 (da) 1994-10-10
ZA877851B (en) 1988-04-22
EP0269841A1 (fr) 1988-06-08
GR3006223T3 (ko) 1993-06-21
EP0269841B1 (fr) 1992-11-11
DE3782619D1 (de) 1992-12-17
AU604767B2 (en) 1991-01-03
CA1296001C (en) 1992-02-18
KR930010559B1 (ko) 1993-10-28
CH670090A5 (ko) 1989-05-12
AU7998087A (en) 1988-04-28
JP2527769B2 (ja) 1996-08-28
IL84266A (en) 1992-02-16
DK551487D0 (da) 1987-10-21
DE3782619T2 (de) 1993-04-22
JPS63122683A (ja) 1988-05-26
DK551487A (da) 1988-04-28

Similar Documents

Publication Publication Date Title
GR3000418T3 (en) Preparation of fibrates
DE3460972D1 (en) Novel 8-chloro-1,5-benzothiazepine derivatives, processes for preparing the same and pharmaceutical compositions
DE69002739D1 (de) Reduzierende zusammensetzung zur dauerhaften haarverformung, die als reduzierendes agens ein aminomercaptoalkylamid oder eines seiner salze enthaelt sowie ihre verwendung in einem verfahren zur dauerhaften haarverformung.
AU527851B2 (en) Purine derivatives
DE19975059I2 (de) (2-Oxo-3-tetrahydrothienylcarbamoyl)-alkylthio-essigsäure, ihre Salze und Ester, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel.
IL92660A0 (en) Enzyme-inhibiting amino acid derivatives,a process for the preparation thereof,compositions containing these,and the use thereof
KR900006301A (ko) 1,4-디아자비사이클로[3.2.2]노난의 제조방법
JPS57106695A (en) Anthracycline g lycoside compound
KR880005131A (ko) 1-히드록시알킬크산틴류, 그의 제조방법 및 그를 함유한 의약품
PT93126A (pt) Processo para a preparacao de eteres carboxialquilicos da 2-amino-7- -hidroxitetralina
IE830278L (en) Corynanthein derivatives, anti-hypertensives
ATE70837T1 (de) Allylmercaptoacetyl-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
DE3164314D1 (en) Azolylalkyl derivatives, process for their preparation and their use as fungicides
ZA836090B (en) Thieno-thiazole derivatives,processes for preparing these compounds,and pharmaceutical compositions thereof
PT88088A (pt) Processo para a preparacao de derivados de piperidina e de composicoes farmaceuticas que os contem
ES476645A1 (es) Procedimiento para la obtencion de derivados aminados de pi-razol (1,5-a)s troazina.
DE3070768D1 (en) 1-((substituted-naphthyl)ethyl)-imidazole derivatives, pharmaceutical compositions containing them and methods of making them
ES8401761A1 (es) Un procedimiento para la preparacion de derivados de 1-(3,4,5-trimetoxicinamoil)-4-aminocarboniletil-piperazina sustituidos.
GB2016002A (en) Amino derivatives of pyrazolo[1,5-A]S.triazine
KR920700210A (ko) 신규 이미다졸 유도체, 그의 제법 및 그의 의약용도
CA2277151A1 (en) Synthesis of acyclic nucleoside derivatives
ZA909766B (en) Substituted amino acid derivatives,process for preparing these and pharmaceutical compositions containing them
ATE75468T1 (de) Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
KR860008999A (ko) N- 페닐-4-페닐-1- 피페라진카복스아미딘의 제조방법
KR920004377A (ko) 피리딘카복실산 아미드 유도체 및 이를 함유하는 약제학적 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19970830

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee